ClinicalTrials.gg
RecruitingNCT07502859Updated Oct 16, 2026

A Study of BEN301 Injection in the Treatment of Autoimmune Diseases

An Early Phase 1 interventional study of CD4⁺ CAR⁺ Foxp3⁺ cells and CD4⁺ CAR⁺ Foxp3⁺ cells in SSC RA SS IIM, sponsored by Beijing Boren Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Beijing Boren Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study aims to investigate the safety, tolerability, and preliminary clinical efficacy of BEN301 Injection in patients with autoimmune diseases.

In patients with autoimmune diseases, Treg cells are typically deficient or dysfunctional. CAR-Treg cell therapy represents a promising strategy for the treatment of autoimmune diseases and may be applicable to a broad spectrum of autoimmune conditions. Preclinical studies have shown that BEN301Injection not only effectively suppresses the aberrant activation of T and B cells in SLE models, but also significantly reduces total lgG secretion and the production of SLE-specific autoantibodies, particularly anti-double-stranded DNA (dsDNA) antibodies. Moreover, no significant treatment-related toxicities were observed.

Treg cell therapy has already demonstrated favorable efficacy in multiple indications, including organ transplantation and autoimmune diseases, with a well-established safety and tolerability profile. Meanwhile, CAR-Treg cell therapy has been actively explored in various autoimmune conditions; several products have shown therapeutic potential, and some patients have already benefited from treatment. These findings highlight the promising prospects of CAR-Treg cell therapy in the management of autoimmune diseases.

02

Conditions studied

  • SSC RA SS IIM
03

In context

Lead sponsor

Beijing Boren Hospital is the lead sponsor of 24 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. General Requirements

    • Voluntary participation in the study, providing written , and willingness and ability to comply with the protocol.
    • Age 18-70 years (inclusive) at the time of signing informed consent.
    • Expected survival ≥ 12 months.
  2. Disease-Specific Criteria 1) Systemic Sclerosis (SSc)

    • Diagnosis of Systemic Sclerosis according to the 2013 ACR/EULAR Classification Criteria for SSc, with a total score ≥ 9.
    • Disease duration (defined as time from onset of first non-Raynaud's phenomenon manifestation) ≤ 6 years. If disease duration > 6 years at screening, the participant may be enrolled if the investigator determines potential benefit and following discussion with the medical monitor of the BEN301 manufacturing site.
    • Evidence of active disease at screening meeting at least one of the following criteria:

      • Modified Rodnan Skin Score (mRSS) ≥ 10 and ≤ 35;
      • Increase in mRSS ≥ 3 points compared to the most recent assessment within 6 months;
      • Increase in mRSS ≥ 2 points with involvement of a new body region compared to the most recent assessment within 6 months;
      • Increase in mRSS ≥ 1 point with involvement of two new body regions within 6 months;
      • Progressive Interstitial Lung Disease (ILD) meeting the following standards:

    Inadequate response or intolerance to at least one prior treatment (including cyclophosphamide, methotrexate, mycophenolate/mycophenolic acid, nintedanib, rituximab, or tocilizumab); AND at least one of the following:

    Evidence of progression on High-Resolution Computed Tomography (HRCT); OR Forced Vital Capacity (FVC) \< 80% predicted, Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) \< 80% predicted, evidence of FVC decrease (absolute) ≥ 10%, or FVC decrease 5%-9% with DLCO decrease ≥ 15%.

    • Inadequate response or intolerance to conventional therapies ( and ).

      2) Rheumatoid Arthritis (RA)

    • Diagnosis of RA according to the 1987 ACR or 2010 ACR/EULAR classification criteria.
    • Inadequate response, intolerance, or to at least one conventional synthetic DMARD (csDMARD) and at least one targeted synthetic DMARD (tsDMARD) or biologic DMARD (bDMARD), failing to achieve remission or low disease activity.
    • Moderate-to-severe active RA at screening, defined as ≥ 4 tender joints (of 68 assessed) and ≥ 4 swollen joints (of 66 assessed).
    • Erythrocyte Sedimentation Rate (ESR) > 28 mm/hr and/or C-reactive protein (CRP) > 10 mg/L.
    • Positive Rheumatoid Factor (RF) and/or Anti-Citrullinated Protein Antibody (ACPA).
    • Duration of RA diagnosis > 6 months. 3) Primary Sjögren's Syndrome (pSS)
    • Meets the 2016 ACR/EULAR Classification Criteria for Sjögren's Syndrome.
    • High disease activity index: ESSDAI ≥ 6 points.
    • Inadequate response or intolerance to conventional therapies (glucocorticoids and immunosuppressants).
    • Positive for Anti-Sjögren's Syndrome A (SSA/Ro) and/or Anti-Sjögren's Syndrome B (SSB/La) antibodies.

      4) Idiopathic Inflammatory Myopathies (IIM) / Dermatomyositis (DM) / Polymyositis (PM)

    • Suspected or confirmed diagnosis of Polymyositis (PM) or Dermatomyositis (DM) according to the 2017 EULAR/ACR Classification Criteria.
    • Moderate-to-severe PM or DM, defined as meeting both Part A and Part B below:

      • Part A: Manual Muscle Testing (MMT-8) total score \< 142.
      • Part B: At least 2 of the following 5 items:

    Physician Global Assessment (PhGA, 10-cm VAS) ≥ 2 cm; Patient Global Assessment (PtGA, 10-cm VAS) ≥ 2 cm; Health Assessment Questionnaire-Disability Index (HAQ-DI) > 0.25; Elevation of any muscle enzyme (CK, LDH, , ALT) ≥ 1.3 × (ULN); Myositis Disease Activity Assessment Tool (MDAAT) global extramuscular activity (10-cm VAS) ≥ 2 cm.

    • Alternatively, presence of active disease: evidence of active muscle inflammation on MRI or muscle within 12 weeks.
  3. Adequate Organ Function

    Within 7 days prior to screening (without transfusion, hematopoietic growth factors within 2 weeks, or medication correction):

    • Bone Marrow:

      • (Hb) ≥ 80 g/L;
      • (ANC) ≥ 1.5 × 10⁹/L;
      • count (PLT) ≥ 50 × 10⁹/L.
    • Renal Function: (CrCl, calculated by Cockcroft-Gault formula, see Appendix 1) ≥ 50 mL/min (without hydration assistance).
    • Hepatic Function: Serum ALT and AST ≤ 2.5 × ULN (exceptions for CK-induced elevations may be determined by the investigator); Total ≤ 1.5 × ULN.
    • Pulmonary Function: Oxygen saturation ≥ 92% on room air without supplemental oxygen; no pleural effusion.
    • Cardiac Function: (LVEF) ≥ 40%; no pericardial effusion; at screening showing no clinically significant abnormalities.
    • Coagulation: Fibrinogen ≥ 1.5 g/L; (APTT) ≤ 1.5 × ULN; Prothrombin Time (PT) ≤ 1.5 × ULN.
  4. Biological Requirements

    • Presence of CD19+ B cells in peripheral blood.
    • Adequate venous access for leukapheresis, without contraindications to leukapheresis.
  5. Reproductive Criteria

    • Women of (WOCBP) must have a negative serum pregnancy test at screening. (Women who are surgically sterile or for at least 2 years are considered non-childbearing).
    • Sexually active WOCBP and male participants must agree to use highly effective from the time of signing informed consent until 1 year after the last study treatment, and must not donate eggs/sperm for assisted reproduction during this period.

Exclusion criteria

Exclusion Criteria:

  1. Severe Renal Disease

    • History of severe nephritis or nephrotic syndrome.
    • Severe is defined as:

      • Prior receipt of any of the following treatments within specified timeframes:

    Prior kidney transplantation; Dialysis or plasmapheresis within 3 months prior to screening; pulse therapy (defined as ≥500 mg/day prednisone or equivalent) within 1 month prior to screening.

    o Requirement for any of the following treatments during the study period: Use of prohibited medications per protocol; Need for dialysis or plasmapheresis; Need or planned kidney transplantation.

  2. Severe Cardiovascular Disease

    • History of severe cardiovascular disease, including but not limited to: symptomatic chronic heart failure requiring intervention, acute myocardial infarction or coronary artery bypass grafting within 6 months, unstable angina, history of severe arrhythmia, or history of stroke.
    • (NYHA) Class III-IV heart failure.
    • interval > 450 ms (male) or > 470 ms (female) on screening (Fridericia formula: QTcF = QT / (RR\^0.33)).
  3. SSc-Specific Exclusions

    • Receipt of oral, intramuscular, or intravenous glucocorticoids (>10 mg/day prednisone or equivalent) within 1 week prior to leukapheresis. (Note: Investigators may consider dose reduction prior to leukapheresis/infusion provided the participant's disease is controlled).
    • Receipt of within 1 week prior to leukapheresis, including but not limited to methotrexate, hydroxychloroquine, cyclosporine A, azathioprine, mycophenolate, sirolimus, colchicine, or D-penicillamine.
  4. RA-Specific Exclusions

    • Use of anti-TNF agents within 8 weeks prior to dosing (or 4 weeks for etanercept).
    • Use of any JAK inhibitor within 2 weeks prior to dosing.
    • Use of other biologics or non-B-cell depleting drugs within fewer than 5 half-lives prior to dosing.
  5. pSS-Specific Exclusions

    • Diagnosis of secondary Sjögren's syndrome (defined as overlap with other or systemic inflammatory diseases, e.g., RA, SLE, scleroderma, or idiopathic inflammatory myopathy).
    • Severe systemic involvement assessed by the investigator, including:

      o Serious vasculitis involving kidneys, digestive system, heart, lungs, or CNS (excluding cutaneous vasculitis);

      o Active CNS or PNS involvement requiring high-dose glucocorticoids;

      o Severe renal involvement (e.g., \< 60 mL/min);

      o Severe pulmonary involvement (e.g., dyspnea at rest, or FVC \< 60% or DLCO \< 40%);

      o Myopathy requiring high-dose glucocorticoids;

      o Lymphoma.

    • Use of sodium hyaluronate eye drops, artificial tears, artificial saliva, or sialogogues (e.g., pilocarpine) within 7 days prior to dosing; use of immunosuppressants (e.g., cyclophosphamide, leflunomide, methotrexate, azathioprine) within 4 weeks prior to dosing; use of JAK inhibitors or other kinase inhibitors within 2 weeks prior to dosing; use of targeted biologics (e.g., Telitacicept, Belimumab, Abatacept, Adalimumab) within 6 weeks prior to dosing.
    • Requirement for medications causing dry mouth/dry eyes during the study.
  6. IIM-Specific Exclusions

    • Participants with a record of Inclusion Body Myositis (IBM), juvenile myositis, drug-induced PM/DM, cancer-associated PM/DM (defined as cancer diagnosed within 3 years of PM/DM diagnosis), or non-inflammatory myopathies (e.g., muscular dystrophies).
    • Patients with PM/DM who have a high risk of .
    • Permanent muscle weakness due to causes other than PM/DM (e.g., stroke) as judged by the investigator.
    • Any of the following prior treatments/procedures:

      • Topical corticosteroids or topical immunomodulators (e.g., tacrolimus) for IIM-associated rash within ≤ 1 week prior to dosing;
      • JAK inhibitors within 2 weeks prior to dosing;
      • Cyclophosphamide, rituximab, or other anti-CD20 antibodies within 12 weeks prior to dosing;
      • Other investigational products within 4 weeks or 5 half-lives (whichever is longer) prior to dosing;
      • Combination therapy with >1 immunosuppressant, >1 antimalarial, or immunosuppressants plus antimalarials within 2 weeks prior to dosing.
  7. Other Autoimmune Diseases • History of other autoimmune diseases excluding the target indications, including Eosinophilic Granulomatosis with Polyangiitis (EGPA), Henoch-Schönlein purpura, cryoglobulinemic vasculitis, anti-glomerular basement membrane disease, Behçet's disease, or Takayasu arteritis.
  8. Malignancy

    • History of malignancy within 5 years prior to enrollment, including patients with tumor-associated PM/DM. Exceptions include: surgically removed and cured non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, low-stage bladder cancer, ductal carcinoma in situ of the breast, or patients cured with no evidence of recurrence in the past 2 years requiring no treatment.
    • Known allergy, hypersensitivity, intolerance, or to BEN301 or any component of the study medications; or history of severe allergic reactions.
  9. Prior Cell Therapy

    • Prior receipt of /allogeneic hematopoietic stem cell transplantation or CAR-T cell therapy.
  10. Recent Procedures/Vaccinations

    • Major surgery, administration, or participation in other clinical trials within 1 month prior to screening.
  11. Active Infection

    • Uncontrolled active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to screening (prophylactic treatment excluded); active tuberculosis (excluded if T-SPOT positive).
  12. Viral Serology

    • Positive serology for (HBsAg positive regardless of HBV-DNA level), (HCVAb positive), (HIV antibody positive), or Syphilis (confirmed TPPA positive) at screening.
  13. Prohibited Medications

    • Use of medications/treatments prohibited by the protocol during screening.
  14. Investigator's Discretion • Any other condition deemed unsuitable for study participation by the investigator, such as certain psychiatric disorders, dementia, suicidal ideation, or poor compliance.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (estimated)

Study arms

  • Experimental
    BEN301 Low-dose group

    Single administration of 1×10⁸ viable CD4⁺ CAR⁺ Foxp3⁺ cells.

    Biological: CD4⁺ CAR⁺ Foxp3⁺ cells

  • Experimental
    BEN301 High-dose group

    Single administration of 3×10⁸ viable CD4⁺ CAR⁺ Foxp3⁺ cells.

    Biological: CD4⁺ CAR⁺ Foxp3⁺ cells

Interventions

  • BiologicalCD4⁺ CAR⁺ Foxp3⁺ cells

    Single administration of 1×10⁸ viable CD4⁺ CAR⁺ Foxp3⁺ cells. Lymphodepletion is generally not required; however, if Treg expansion is suboptimal, lymphodepletion may be administered as needed, or low-dose IL-2 may be combined. The recommended lymphodepletion regimens 33 include: * Cyclophosphamide monotherapy (CTX 900-1000 mg/m² on day -3, or CTX 300 mg/m² from day -5 to day -3); * or cyclophosphamide combined with fludarabine (12.5-25 mg/m² from day -5 to day -3); * or low-dose IL-2 administered after cell infusion.

  • BiologicalCD4⁺ CAR⁺ Foxp3⁺ cells

    Single administration of 3×10⁸ viable CD4⁺ CAR⁺ Foxp3⁺ cells. Lymphodepletion is generally not required; however, if Treg expansion is suboptimal, lymphodepletion may be administered as needed, or low-dose IL-2 may be combined. The recommended lymphodepletion regimens 33 include: * Cyclophosphamide monotherapy (CTX 900-1000 mg/m² on day -3, or CTX 300 mg/m² from day -5 to day -3); * or cyclophosphamide combined with fludarabine (12.5-25 mg/m² from day -5 to day -3); * or low-dose IL-2 administered after cell infusion.

06

What researchers measure

Primary outcomes

  1. DLT

    Proportion of participants experiencing dose-limiting toxicity (DLT) within 28 days after infusion; determination of the MTD or RP2D

    Time frame: days 28

  2. AE

    Incidence and proportion of adverse events occurring after infusion.

    Time frame: AEs occurring from informed consent signing through Week 12 post-infusion. Thereafter, only AEs related to the investigational product will be collected through study completion, an average of 2 years.

Secondary outcomes

  1. Modified Rodnan Skin Score (mRSS)

    Change from baseline in modified Rodnan Skin Score (mRSS) at Week 12 after the first infusion of BEN301 Injection. The minimum value of the modified Rodnan skin scale (MRSS) is 0 points, and the maximum value is 51 points. The higher the score, the more severe the degree of skin sclerosis, that is, the worse the result. MRSS quantifies the skin involvement of systemic sclerosis by evaluating the skin hardness of 17 parts of the body. 0 points represent normal skin and 3 points represent severe thickening. The higher the total score, the more extensive and severe skin fibrosis, which is associated with disease activity and poor prognosis.

    Time frame: Week 12

  2. Simplified Disease Activity Index (SDAl) score

    SDAl score at Week 12 after the first infusion of BEN301 Injection; percentage of patients achieving SDAl low disease activity and clinical remission. SDAI score exceeding 26 is considered high disease activity; exceeding 11 and not greater than 26, moderate disease activity; exceeding 3.3 and not greater than 11, low disease activity.

    Time frame: Week 12

  3. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAl) score

    Change from baseline in overall disease activity (ESSDAl) at Week 12 after the first infusion of BEN301 Injection. The ESSDAI is a validated tool used in clinical studies to measure the systemic disease activity in participants with primary Sjogren's syndrome. The ESSDAI includes 12 domains divided into 4 activity levels, where zero represents no activity. A higher score means a worse outcome.

    Time frame: Week 12

  4. Total Improvement Score (TIS)

    Change from baseline in Myositis Response Criteria TIS scores at Week 12 after the first infusion of BEN301 Injection. The Total Improvement Score (TIS) is a standardized composite measure developed to quantify treatment response in idiopathic inflammatory myopathies(IIM). The TIS ranges from 0 to 100,with higher scores reflecting greater improvement.

    Time frame: Week 12

  5. Cytokine analysis

    Monitoring changes in peripheral blood cytokine levels before and after infusion of BEN301 Injection.

    Time frame: Venous blood samples will be collected prior to infusion of BEN301Injection and on Days 1, 3, 7, 10, 14,21, and Weeks 4, 8, 12, 16, 24, 48,and 96 post-infusion .

07

Study locations

1 of 2 sites recruiting
  • Boren Hospital, Beijing.
    Beijing, Beijing Municipality 100070, China
    Recruiting
  • Shanghai Jiaotong University School of Medicine, Renji Hospital
    Shanghai, Shanghai Municipality 200127, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Mar 2026 → Apr 2026, primary completion Feb 2029 → Apr 2027 and completion Feb 2029 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Mar 31, 2026
StartActual
Apr 1, 2026was Mar 2026
Primary completionEst.
Apr 30, 2027was Feb 2029
CompletionEst.
Apr 30, 2027was Feb 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Boren Hospital, Beijing. · Beijing, Chinano status→Recruiting
  • Shanghai Jiaotong University School of Medicine, Renji Hospital · Shanghai, Chinano status→Not yet recruiting
Oct 16, 2026
Start date
Mar 25, 2026→Apr 1, 2026 (actual)
Oct 16, 2026
Primary completion
Feb 28, 2029→Apr 30, 2027
Oct 16, 2026
Study completion
Feb 28, 2029→Apr 30, 2027
Oct 16, 2026
Enrollment
24→2
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Boren Hospital, Beijing. · Beijing, Chinano status→Recruiting
    • Shanghai Jiaotong University School of Medicine, Renji Hospital · Shanghai, Chinano status→Not yet recruiting
    Start date Mar 25, 2026→Apr 1, 2026 (now actual)
    Primary completion Feb 28, 2029→Apr 30, 2027
    Study completion Feb 28, 2029→Apr 30, 2027
    Enrollment 24→2
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07502859
Lead sponsor
Beijing Boren Hospital
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Apr 1, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Yajing Zhang, phD
Contact
23975701@qq.com
+86 18601333856

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion